Acceptability of intanza® 15 μg intradermal influenza vaccine in Belgium during the 2010-2011 influenza season

Advances in Therapy

Volumn 29, Issue 6, 2012, Pages 562-577

  Dhont, Patrick A ^a   Albert, Adelin ^b   Brenders, Patrick ^c   Podwapinska, Anna ^c   Pollet, Ann ^c   Scheveneels, Dirk ^d   Tihon, François ^c   Verheyden, Ilse ^c   Victor, Jan ^c   Samson, Sandrine I ^e  

^a Sanofi Pasteur MSD   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c NONE   (Belgium)

^d NONE   (Belgium)

^e SANOFI PASTEUR   (France)

Author keywords

Belgium; Elderly individuals; General practitioners; Immunosenescence; Intanza; Intradermal influenza vaccine; Microneedle injection system; Survey; Vaccination acceptability

Indexed keywords

INFLUENZA VACCINE;

ADULT; AGED; ARTICLE; BELGIUM; CLINICAL ASSESSMENT; CLINICAL PRACTICE; DRUG USE; FEMALE; GENERAL PRACTITIONER; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PHYSICIAN ATTITUDE; QUESTIONNAIRE; SEASONAL INFLUENZA;

EID: 84866498231     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-012-0025-9     Document Type: Article

References (29)

1. World Health Organization. Influenza vaccines. Wkly Epidemiol Rec. 2005;80:279-87.
2. World Health Organization. Fifty-sixth World Health Assembly (WHA). Prevention and control of influenza pandemics and annual epidemics. WHA 10th plenary meeting, 28 May 2003. Available at: Apps.who.int/gb/archive/pdf-files/ WHA56/ea56r19. pdf. Accessed Jan 5 2012.
3. Council of the European Union. Council recommendation of 22 December 2009 on seasonal influenza vaccination (2009/1019/EU). Off J Eur Union. 2009;348:71-72. Available at: Http://eurlex. europa.eu/LexUriServ/LexUriServ.do? uri=OJ:L:2009:3 48:0071:0072:EN:PDF. Accessed Jan 5 2012.
4. Superior Health Council. Publication of the Superior Health Council No. 8682, September 1, 2010. Vaccination against seasonal influenza. Winter Season 2010-2011. [Article in French]. Available at: Http://www.health.belgium.be/ internet2Prd/groups/public/@public/@shc/documents/ie2divers/19064111-fr.pdf. Accessed May 21 2012.
5. Lui KJ, Kendal AP. Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. Am J Public Health. 1987;77:712-16. (Pubitemid 17084513)
6. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179-86. (Pubitemid 36068705)
7. Rizzo C, Bella A, Viboud C, et al. Trends for influenza-related deaths during pandemic and epidemic seasons, Italy, 1969-2001. Emerg Infect Dis. 2007;13:694-9. (Pubitemid 46698731)
8. Nichol KL, Nordin J, Mullooly J, et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med. 2003;348:1322-32. (Pubitemid 36384099)
9. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med. 2007;357:1373-81. (Pubitemid 47535592)
10. Mereckiene J, Cotter S, D'Ancona F, et al. Differences in national influenza vaccination policies across the European Union, Norway and Iceland 2008-2009. Euro Surveill. 2010;15.pii:19700.
11. De Bruyn K, Saevels J. Influenza vaccination in community pharmacies 2009/2010. J Pharm Belg. 2010;3:75-80. (Article in French).
12. De Bruyn K, Hamelinck W. Influenza vaccines dispensed in community pharmacies during the 2010-2011 flu season. J Pharm Belg. 2011;4:117- 21. (Article in French).
13. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: A quantitative review. Vaccine. 2006;24:1159-69. (Pubitemid 43202262)
14. Castilla J, Moran J, Martinez-Artola V, et al. Effectiveness of trivalent seasonal and monovalent influenza A(H1N1)2009 vaccines in population with major chronic conditions of Navarre, Spain: 2010/11 mid-season analysis. Euro Surveill. 2011;16.pii:19799.
15. Kissling E, Valenciano M, Cohen JM, et al. I-MOVE multi-centre case control study 2010-11: Overall and stratified estimates of influenza vaccine effectiveness in Europe. PLoS One. 2011;6:e27622.
16. Vankerckhoven V, Van Damme P. Clinical studies assessing immunogenicity and safety of intradermally administered influenza vaccines. Expert Opin Drug Deliv. 2010;7:1109-25.
17. Arnou R, Frank M, Hagel T, Prébet A. Willingness to vaccinate or get vaccinated with an intradermal seasonal influenza vaccine: A survey of general practitioners and the general public in France and Germany. Adv Ther. 2011;28:555-65.
18. European Commission. Commission decision of 24.2.2009 granting marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council for "INTANZA - Influenza Vaccine (split virion, inactivated)", a medicinal product for human use. Available at: Http://ec.europa.eu/health/documents/communityregister/2009/2009022454169/ dec-54169-en.pdf. Accessed Jan 5 2012.
19. Holland D, Booy R, De Looze F, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: A randomized controlled trial. J Infect Dis. 2008;198:650-8.
20. Arnou R, Icardi G, De Decker M, et al. Intradermal influenza vaccine for older adults: A randomized controlled multicenter phase III study. Vaccine. 2009;27:7304-12.
21. Van Damme P, Arnou R, Kafeja F, et al. Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: A randomised comparative study. BMC Infect Dis. 2010;10:134.
22. Reygrobellet C, Viala-Danten M, Meunier J, Weber F, Nguyen VH. Perception and acceptance of intradermal influenza vaccination: Patient reportedoutcomes from phase 3 clinical trials. Hum Vaccin. 2010;6:336-45.
23. Newcombe RG. Two-sided confidence intervals for the single proportion: Comparison of seven methods. Stat Med. 1998;17:857-72. (Pubitemid 28185165)
24. Eizenberg P, Booy R, Naser N, et al. Acceptance of Intanza® 9 μg intradermal influenza vaccine in routine clinical practice in Australia and Argentina. Adv Ther. 2011;28:640-9.
25. Prymula R, Usluer G, Altinel S, Sichova R, Weber F. Acceptance and opinions of Intanza/IDflu intradermal influenza vaccine in the Czech Republic and Turkey. Adv Ther. 2012;29:41-52.
26. Organisation for Economic Co-operation and Development (OECD). OECD Health Data 2011. Health care activities - vaccination rates against influenza for people 65 and over. Available from: Http://www.oecd.org/document/16/0,3746, en-2649-37407-2085200-1-1-1-37407,00.html. Accessed Jan 5 2012.
27. Dedoukou X, Nikolopoulos G, Maragos A, Giannoulidou S, Maltezou HC. Attitudes towards vaccination against seasonal influenza of health-care workers in primary health-care settings in Greece. Vaccine. 2010;28:5931-3.
28. Virseda S, Restrepo MA, Arranz E, et al. Seasonal and pandemic A (H1N1) 2009 influenza vaccination coverage and attitudes among health-care workers in a Spanish University Hospital. Vaccine. 2010;28:4751-7.
29. Tanguy M, Boyeau C, Pean S, Marijon E, Delhumeau A, Fanello S. Acceptance of seasonal and pandemic a (H1N1) 2009 influenza vaccination by healthcare workers in a French teaching hospital. Vaccine. 2011;29:4190-4.